{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069147","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.371504+00:00","generated_at":"2026-05-22T00:37:33.687638+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neumora Q1 net loss $68M, secures $125M venture debt; navacaprant Ph3 data in 2026","bullets":["Net loss $68.0M in Q1 2025, up from $53.7M in Q1 2024; R&D expense $52.2M (incl. $6.3M final Amgen costs).","Cash, equivalents and marketable securities $249.4M as of March 31; plus $20M drawn from K2 HealthVentures extends cash runway into 2027.","Entered $125M venture debt facility with K2 HealthVentures; $20M drawn, additional $20M available by Dec 31, 2025, $85M milestone-based.","Navacaprant KOASTAL-3 topline data expected Q1 2026, KOASTAL-2 Q2 2026; NMRA-511 AD agitation data around end of 2025.","M4 positive allosteric modulator (PAM) program expected to enter clinic in mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069147","json":"https://secwatch.observer/filing/0000950170-25-069147.json","markdown":"https://secwatch.observer/filing/0000950170-25-069147.md","text":"https://secwatch.observer/filing/0000950170-25-069147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025069147/0000950170-25-069147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025069147/nmra-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:37:33.687638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}